Results 41 to 50 of about 29,746 (162)

Determination of the reference value of the incremental cost-efficacy and cost-utility coefficient in Russia in oncology

Качественная клиническая практика, 2018
The share of antineoplastic drug dossiers submitted to reimbursement in Russia raised from 15% in 2014 to 28% in 2017. The effectiveness and safety of innovative anti-cancer therapy is higher comparing to widely used traditional treatments.
A. S. Kolbin, A. A. Kurylev
doaj   +1 more source

Toward a Consensus on the QALY

Value in Health, 2009
Earlier versions of the other articles in this Value in Health Special Issue, Moving the QALY Forward: Building a Pragmatic Road (articles 2–6) were presented at an ISPOR Development Workshop on “Moving the QALY Forward: Building a Pragmatic Road” held in Philadelphia from November 6–8, 2007.
Drummond, Michael, Brixner, Diana, Gold, Marthe, Kind, Paul, McGuire, Alistair, Nord, Erik   +5 more
openaire   +2 more sources

Preferences, needs and QALYs. [PDF]

Journal of Medical Ethics, 1996
Quality Adjusted Life Years (QALYs) have become a household word among health economists. Their use as a means of comparing the value of health programmes and medical interventions has stirred up controversy in the medical profession and the academic community.
openaire   +3 more sources

QALY: Quality Adjusted Life Year

Medicine Science, 2012
Nufusun yaslanmasi ve yaslilik donemi hastaliklar ile kronik hastaliklarin one cikmasi verilen saglik hizmetlerinin sadece saglik duzeyi uzerine degil yasam kalitesine etkisinin de onemli bir cikti olarak degerlendirilmesini getirmistir.
Selale Sahin, Selime Toprak, Erdinc Unal
doaj   +1 more source

COST-UTILITY ANALYSIS PATIENTS WITH LOW BACK PAIN AFTER TREATMENT INTRAOSSEOUS BLOCKADES

Фармакоэкономика, 2015
a total of 62 patients with a diagnosis of low back pain. Low back pain patients were randomized of two group. Patients of the first (main) group received a course of intraosseous blockades, while patients of the second (control group) received a course ...
M. V. Yakovlev, A. U. Kulikov, E. L. Sokov, I. E. Kornilova   +3 more
doaj  

Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

Health Technology Assessment
Background Renal cell carcinoma is the most common type of kidney cancer, comprising approximately 85% of all renal malignancies. Patients with advanced renal cell carcinoma are the focus of this National Institute for Health and Care Excellence multiple
Nigel Fleeman, Rachel Houten, Sarah Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell   +13 more
doaj   +1 more source

Фармакоэкономический анализ использования лираглутида в составе комбинированной терапии в лечении сахарного диабета 2-го типа

Фармакоэкономика, 2015
The analysis goal is to determine the cost-effectiveness of liraglutideas add-on to metformin in for patients with type 2 diabetes in condition of the Russian health care system.
A. Yu. Kulikov, I. V. Novikov
doaj  

Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation

Health Technology Assessment, 2013
Background: Dementia is one of the most common and serious disorders in later life and the economic and personal cost of caring for people with dementia is immense. There is a need to be able to evaluate interventions in dementia using cost-effectiveness
B Mulhern, D Rowen, J Brazier, S Smith, R Romeo, R Tait, C Watchurst, K-C Chua, V Loftus, T Young, D Lamping, M Knapp, R Howard, S Banerjee   +13 more
doaj   +1 more source

QALYs: Some Challenges

Value in Health, 2009
In the preceding article, Weinstein et al. [1] explain the QALYconcept, its methods, and their underlying assumptions. Anumber of interesting themes for discussion arise from thisfactual presentation. We restrict ourselves to addressing fourissues that we deem particularly challenging.As a general background for our selection of issues, we reit-erate a
Nord, Erik, Daniels, Norman, Kamlet, Mark   +2 more
openaire   +2 more sources

Cost-effectiveness analysis of robotic-arm assisted versus manual total knee arthroplasty in the UK

Bone & Joint Open
Aims: The aim of this study was to estimate the additional cost per quality-adjusted life-year (QALY) of robotic-assisted total knee arthroplasty (rTKA) compared to manually performed total knee arthroplasty (mTKA).
Gurdeep S. Sagoo, Nick D. Clement, Yaneth Gil-Rojas, Nawaraj Bhattarai, Steven Galloway, Jenny B. Baron, Karen Smith, David J. Weir, David J. Deehan   +8 more
doaj   +1 more source